CoreCap Advisors LLC Purchases 3,077 Shares of Biogen Inc. $BIIB

CoreCap Advisors LLC grew its holdings in Biogen Inc. (NASDAQ:BIIB) by 1,546.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,276 shares of the biotechnology company’s stock after purchasing an additional 3,077 shares during the quarter. CoreCap Advisors LLC’s holdings in Biogen were worth $577,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in BIIB. Elevation Point Wealth Partners LLC bought a new stake in Biogen during the 2nd quarter valued at approximately $25,000. Accredited Wealth Management LLC increased its position in Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after buying an additional 185 shares during the period. WFA of San Diego LLC bought a new position in Biogen in the 2nd quarter worth approximately $32,000. True Wealth Design LLC lifted its holdings in shares of Biogen by 62.9% during the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after buying an additional 90 shares during the last quarter. Finally, GoalVest Advisory LLC acquired a new position in shares of Biogen during the fourth quarter worth approximately $35,000. 87.93% of the stock is currently owned by institutional investors.

Biogen Trading Up 2.0%

Shares of BIIB stock opened at $187.57 on Tuesday. Biogen Inc. has a 12-month low of $110.04 and a 12-month high of $202.41. The company has a market capitalization of $27.53 billion, a P/E ratio of 21.29, a P/E/G ratio of 1.46 and a beta of 0.15. The firm has a 50-day moving average price of $185.83 and a 200 day moving average price of $170.70. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on BIIB shares. HC Wainwright raised their price objective on shares of Biogen from $194.00 to $228.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Biogen in a research note on Monday, December 29th. Morgan Stanley set a $190.00 price target on shares of Biogen in a report on Sunday, February 8th. HSBC raised their price target on shares of Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a research report on Tuesday, March 17th. Finally, Wells Fargo & Company boosted their price objective on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a report on Sunday, February 8th. Twelve analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $205.31.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: FDA approves a higher‑dose SPINRAZA regimen for spinal muscular atrophy — the approval (based on the DEVOTE study) expands an existing revenue-driving product, will be available in the U.S. in coming weeks, and is already approved in the EU, Switzerland and Japan. This is the primary catalyst lifting the stock today. Reuters: FDA approves higher-dose of Biogen’s genetic disorder drug
• Positive Sentiment: Analysts and company commentary see the high‑dose Spinraza approval as supporting Biogen’s long‑term rare‑disease franchise and revenue stability after prior regulatory delays were resolved. Proactive: High-dose Spinraza approval seen supporting long-term growth
• Positive Sentiment: Biogen reported a second positive Phase II result for litifilimab in cutaneous lupus erythematosus (CLE), adding to the pipeline narrative that could deliver new commercial opportunities if later‑stage trials succeed. The Pharma Letter: Biogen’s second positive Phase II litifilimab trial in CLE
• Neutral Sentiment: Market commentary highlights BIIB outperformed peers on a strong trading day as investors digested the Spinraza approval and clinical updates; that market reaction reflects positive sentiment but could be short‑lived if follow‑through is absent. MarketWatch: Biogen stock outperforms competitors
• Neutral Sentiment: Several analysts (Needham, Morgan Stanley and others) are maintaining Hold ratings and modest price targets — signaling that while the news is constructive, many see limited near‑term upside until commercial uptake, pricing/reimbursement and larger late‑stage data are clearer. TipRanks: Encouraging early data but competitive and clinical risks support a neutral hold
• Negative Sentiment: Analysts warn competition in lupus indications, modest Phase II effects relative to rivals, and clinical/regulatory risk could limit upside; investors should watch uptake, pricing negotiations for the new Spinraza dose, and execution on late‑stage programs. TipRanks: Balanced but constrained upside — Hold

Insider Activity at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.18% of the stock is owned by insiders.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.